About US: Leadership

FOCUSED LEADERSHIP

The AVITA Medical leadership team is comprised of experienced industry executives who bring a critical set of skills to the organization to support long-term growth.

AVITA Medial Dr Michael Perry CEO

Dr. Michael Perry

Chief Executive Officer


AVITA Medical David McIntyre CFO

David McIntyre

Chief Financial Officer


AVITA Medical Erin Liberto CCO

Erin Liberto

Chief Commercial Officer


AVITA Medical Andrew Quick CTO

Andrew Quick

Chief Technology Officer


AVITA Medical Donna Shiroma General Counsel

Donna Shiroma

General Counsel


Dr. Michael Perry

Chief Executive Officer

Appointed as Chief Executive Officer of AVITA Medical in June 2017 after serving on the Board since February 2013, Dr. Perry brings extensive experience across the global pharmaceutical value chain for healthcare products spanning diverse therapeutic areas, including substantial expertise in cell therapies and cell-based gene therapies. In his career, he has been materially involved in the successful development and commercial launch of more than 30 prescription products, 14 of which achieved blockbuster status.

Prior to joining AVITA Medical, Dr. Perry’s leadership positions included Chief Scientific Officer of Novartis’ Cell and Gene Therapy Unit from 2014-2017; Vice President and Global Head of Stem Cell Therapy for Novartis Pharmaceuticals Corp. from 2012-2014.

With additional positions held as Global Head of R&D at Baxter Healthcare; President and CEO of Cell & Gene Therapy at Novartis affiliates Systemix Inc. and Genetic Therapy, Inc.; Vice President of Regulatory Affairs at Sandoz Pharmaceuticals Corporation; Director of Regulatory Affairs at Schering-Plough Corporation; and Venture Partner with Bay City Capital, LLC, Dr. Perry brings successful global management, guidance and forward direction to AVITA Medical. Since 2011, Dr. Perry has served as a Director with Arrowhead Pharmaceutical expanding his reach in influential medical growth.

 

David McIntyre

Chief Financial Officer

A seasoned executive with more than 20 years of experience, Mr. McIntyre has served in senior financial, legal and operational roles across multinational and growth-stage entities. Most recently, Mr. McIntyre served as a Partner with Apple Tree Partners (ATP), a multibillion-dollar venture capture and growth equity fund focused exclusively on life sciences. At ATP, Mr. McIntyre was responsible for the medical device portfolio, together with various operating and Board functions, including acting as Executive Vice President, Chief Financial Officer and Head of Technical Operations at Braeburn, Inc.

Prior to ATP, Mr. McIntyre was Executive Vice President, Chief Financial Officer and Chief Operating Officer at HeartWare® International, Inc. (previously ASX:HIN; NASDAQ: HTWR) where he oversaw HeartWare’s financial, supply chain and operating functions as it transitioned from pre-clinical stage through commercialization across more than 20 countries. Prior to HeartWare, Mr. McIntyre practiced as a senior attorney in private practice specializing in corporate, mergers and acquisitions and equity capital markets with Baker & McKenzie and KPMG as well as holding various senior financial roles in multi-national companies, including within the Rio Tinto Group of companies.

 

Erin Liberto

Chief Commercial Officer

An accomplished global marketing and strategy leader whose proficiency at long-term planning has led to numerous successful product launches across the U.S, Europe and Asia Pacific, Mrs. Liberto brings more than 15 years of multifaceted global commercial experience developing, launching, managing, and optimizing healthcare portfolios with products that span therapeutic and aesthetic indications for international organizations including Allergan and Johnson & Johnson.

In her career, Mrs. Liberto has successfully launched more than a dozen products across diverse geographical markets. She has proven success in rapidly identifying business opportunities and formulating corresponding portfolio and brand strategies which drive revenue and global market share growth.

Erin holds an International MBA with a concentration in Global Marketing from Thunderbird School of Global Management in Arizona and a Bachelor of Commerce from McMaster University in Canada.

 

Andrew Quick

Chief Technology Officer

With more than 25 years of experience in medical device design, development, clinical research and medical affairs, Mr. Quick joined AVITA Medical in 2010 and is the Chief Technology Officer. Mr. Quick has held leadership positions in the development of diagnostic instrumentation and active implantable therapeutics, including most recently with Boston Scientific Neuromodulation / Advanced Bionics where he led U.S. investigational device and post-market clinical research in the cochlear implant business.

Mr. Quick holds Bachelor of Science and Master of Science degrees in Biomedical Engineering from Boston University.

 

Donna Shiroma

General Counsel

With more than 20 years of legal and compliance experience in the pharmaceutical and medical device industries, Ms. Shiroma has played an instrumental role in transitioning companies from clinical to commercial entities. Prior to joining AVITA Medical, she served in roles of increasing responsibility as Corporate Counsel, General Counsel, Vice President of Legal, Chief Privacy and Compliance Officer, and Chief Commercial Officer for Ascend Therapeutics, PDL BioPharma, and several Johnson & Johnson companies.

This website stores cookies on your computer. These cookies are used to improve your website experience and provide more personalized services to you, both on this website and through other media. To find out more about the cookies we use, see our privacy policy.